U.S. District Judge Sheri Polster Chappell ordered a mandatory settlement conference on November 20, 2025, in a contentious civil case involving Humanigen insider trading allegations against former CSO Dale Chappell, referring parties to non-assigned magistrate mediation after impasse in prior talks. This directive—under Middle District of Florida’s Local Rule 2.2.2—escalates efforts to resolve the $38 million fraud claim without trial, requiring good-faith attendance and confidential briefs five days prior, per court filings. For litigation trackers, Chappell’s order—echoing her policy on all civil referrals—highlights ADR’s efficacy, with 75% resolution rates in FLMD, though failure risks sanctions up to $500,000.
Case backdrop: Chappell allegedly sold $38 million in Humanigen shares via 10b5-1 plans in 2021, exploiting nonpublic FDA rejection of COVID drug Lenzilumab, per DOJ indictment (24-CR-243). Status conference rescheduled to December 8 before Judge Karen M. in Camden adds pressure, with mediation focusing on discovery disputes and expert stipulations under FRCP 16. Technically, Chappell’s hybrid format—virtual/in-person—mandates lead counsel presence, barring electronic devices and enforcing silent mode, to streamline issues like baseless claims and evidence admissibility.
Broader implications: This aligns with Virginia’s JSC program—launched 2003 for retired judges—and California’s mandatory conferences under CPLR 3408 for foreclosures, slashing dockets 20% via per diem vouchers. Risks: Non-compliance invites Rule 37 sanctions, while 30-day objection windows allow mediation switches.
As December deadlines loom, Chappell’s order—potentially averting 2026 trial—epitomizes judicial efficiency, where conferences aren’t delays—they’re gateways to resolution in ADR’s evolving landscape.
